Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 1/2008

01-01-2008 | Invited Manuscript

New prospects for management and treatment of inoperable and recurrent skull base meningiomas

Authors: Mahlon D. Johnson, Burak Sade, Michael T. Milano, Joung H. Lee, Steven A. Toms

Published in: Journal of Neuro-Oncology | Issue 1/2008

Login to get access

Abstract

Skull base, including optic nerve, cavernous sinus, clival and foramen magnum tumors represent a major challenge for neurosurgeons and neuro-oncologists. Growth regulatory signaling pathways for these tumors are of increasing interest as potential targets for new chemotherapy. Those differentially activated in various grades of meningiomas are currently being identified as well. This article reviews some recent findings pathways that appear to regulate meningioma growth. Potential targets for novel therapies are also discussed.
Literature
1.
Bondy M, Ligon BL (1996) Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol 29:197–205PubMedCrossRef
2.
Jaaskelainen J (1986) Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 637 patients. A multivariate analysis. Surg Neurol 26:461–469
3.
Stafford SL, Perry A, Suman VJ et al (1998) Primarily resected meningiomas: outcomes and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988. Mayo Clin Proc 73:936–942PubMed
4.
Perry A, Stafford SL, Scheithauer BW et al (1997) Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21:1455–1465PubMedCrossRef
5.
Maroon JC, Kennerdell JS, Vidovich DV, Alba A, Sternau L (1994) Reccurent spheno-orbital meningioma. J Neurosurg 80:202–208PubMed
6.
Black PM, Villavicencio AT, Rhouddou C, Loeffler JS (2001) Aggressive surgery and focal radiation in the management of meningiomas of the skull base: Preservation of function with the maintenance of local control. Acta Neurochir 143:555–562CrossRef
7.
Drummond KJ, Zhu J-J, Black PM (2004) Meningiomas: updating basic science, management, and outcome. The Neurologist 10:113–130PubMedCrossRef
8.
Kim Y-J, Ketter R, Henn W et al (2006) Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters. Virchows Arch 449:529–538PubMedCrossRef
9.
Manelfe C, Lasjaunias P, Ruscalleda J (1986) Preoperative embolization of intracranial meningiomas. Am J Neuroradiol 7:963–972PubMed
10.
Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22–39PubMed
11.
Dolenc V (1983) Direct microsurgical repair of intracavernous vascular lesions. J Neurosurg 58:824–831PubMed
12.
O’Sullivan MG, van Loveren HR, Tew JM Jr (1997) The surgical respectability of meningiomas of the cavernous sinus. Neurosurgery 40:238–237PubMedCrossRef
13.
Pamir MN, Kilic T, Bayrakli F, Peker S (2005) Changing strategy of cavernous sinus meningiomas: experience of a single institution. Surg Neurol 64(Suppl 2):S58–66PubMedCrossRef
14.
Maruyama K, Shin M, Kurita H, Hawahara N, Morita A, Kirino T (2004) Proposed treatment strategy for cavernous sinus meningiomas: prospective study. Neurosurgery 55: 1068–1075PubMedCrossRef
15.
Couldwell WT, Kan P, Liu JK, Apfelbaum RI (2006) Decompression of cavernous sinus meningioma for preservation and improvement of cranial nerve function. J Neurosurg 105:148–152PubMed
16.
Honeybul S, Neil-Dwyer G, Lang DA, Evans BT, Ellison DW (2001) Sphenoid wing meningioma en plaque: A clinical review. Acta Neurochir (Wien) 143:749–758CrossRef
17.
Shrivastava RK, Sen C, Costantino P, Rocca RD (2005) Sphenoorbital meningiomas: surgical limitations and lesions learned in their long-term management. J Neurosurg 103:491–497PubMed
18.
Schick U, Bleyen J, Bani A, Hassler W (2006) Management of meningiomas en plaque of the sphenoid wing. J Neurosurg 104:208–214PubMed
19.
Shrivastava RK, Sen C, Costantino P, Rocca RD (2005) Sphenoorbital meningiomas: surgical limitations and lesions learned in their long-term management. J Neurosurg 103:491–497PubMed
20.
Maroon JC, Kennerdell JS, Vidovich DV, Abla A, Sternau L (1994) Recurrent spheno-orbital meningioma. J Neurosurg 80:202–208PubMed
21.
Little K, Friedman AH, Sampson JH, Wanibuchi M, Fukushima T (2005) Surgical management of petroclival meningiomas: Defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients. Neurosurgery 56:546–559PubMedCrossRef
22.
Goel A, Muzumdar D (2004) Conventional posterior fossa approach for surgery on petroclival meningiomas: a report on an experience with 28 cases. Surg Neurol 62:332–340PubMedCrossRef
23.
Roberti F, Sekhar LN, Kalavakonda C, Wright DC (2001) Posterior fossa meningiomas: surgical experience in 161 cases. Surg Neurol 56:8–21PubMedCrossRef
24.
Couldwell WT, Fukushima T, Giannotta SL, Weiss MH (1996) Petroclival meningiomas: surgical experience with 109 cases. J Neurosurg 84:20–28PubMed
25.
Samii M, Tatagiba M, Carvalho GA (1999) Resection of large petroclival meningiomas by the simple retrosigmoid route. J Clin Neurosci 6:27–30PubMedCrossRef
26.
Jung HW, Yoo H, Paek SH, Choi KS (2000) Long-term outcome and growth rate of subtotally resected petroclival meningiomas: experience with 38 cases. Neurosurgery 46:567–575PubMedCrossRef
27.
George B, Lot G (1995) Foramen magnum meningiomas: a review from personal experience of 37 cases and from a cooperative study of 106 cases. Neurosurg Quarterly 5:149–167
28.
Bassiouni H, Ntoukas V, Siamak A et al (2006) Foramen magnum meningiomas: clinical outcome after microsurgical resection via a posterolateral suboccipital retrocondylar approach. 59:1177–1187
29.
Schick U, Dott U, Hassler W (2004) Surgical management of meningiomas involving the optic nerve sheath. J Neurosurg 101:951–959PubMed
30.
Roser F, Nakamura M, Martini-Thomas R, Samii M, Tatagiba M (2006) The role of surgery in meningiomas involving the optic nerve sheath. Clin Neurol Neurosurg 108:470–476PubMedCrossRef
31.
Barbaro NM, Gutin PH, Wilson CB et al (1987) Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery 20:525–528PubMedCrossRef
32.
Taylor BW Jr, Marcus RB Jr, Friedman WA et al (1988) The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 15:299–304PubMedCrossRef
33.
Wara WM, Sheline GE, Newman H et al (1975) Radiation therapy of meningiomas. Am J Roentgenol Radium Ther Nucl Med 123:453–548PubMed
34.
Goldsmith BJ, Wara WM, Wilson CB et al (1994) Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 80:195–201PubMed
35.
Miralbell R, Linggood RM, de la Monte S et al (1992) The role of radiotherapy in the treatment of subtotally resected benign meningiomas. J Neurooncol 13:157–164PubMedCrossRef
36.
Deinsberger R, Tidstrand J, Sabitzer H et al (2004) LINAC radiosurgery in skull base meningiomas. Minim Invasive Neurosurg 47:333–338PubMedCrossRef
37.
Kreil W, Luggin J, Fuchs I et al (2005) Long term experience of gamma knife radiosurgery for benign skull base meningiomas. J Neurol Neurosurg Psychiatry 76:1425–1430PubMedCrossRef
38.
Lee JY, Kondziolka D, Flickinger JC et al (2007) Radiosurgery for intracranial meningiomas. Prog Neurol Surg 20:142–149PubMed
39.
Mindermann T, de Rougemont O (2004) The significance of tumor location for Gamma Knife treatment of meningiomas. Stereotact Funct Neurosurg 82:194–195PubMedCrossRef
40.
Nicolato A, Giorgetti P, Foroni R et al (2005) Gamma knife radiosurgery in skull base meningiomas: a possible relationship between somatostatin receptor decrease and early neurological improvement without tumour shrinkage at short-term imaging follow-up. Acta Neurochir (Wien) 147:367–374; discussion 374–375CrossRef
41.
Pollock BE, Stafford SL (2005) Results of stereotactic radiosurgery for patients with imaging defined cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys 62:1427–1431PubMedCrossRef
42.
Selch MT, Ahn E, Laskari A et al (2004) Stereotactic radiotherapy for treatment of cavernous sinus meningiomas. Int J Radiat Oncol Biol Phys 59:101–111PubMedCrossRef
43.
Zachenhofer I, Wolfsberger S, Aichholzer M et al (2006) Gamma-knife radiosurgery for cranial base meningiomas: experience of tumor control, clinical course, and morbidity in a follow-up of more than 8 years. Neurosurgery 58:28–36; discussion 28–36PubMedCrossRef
44.
Chen JC, Giannotta SL, Yu C et al (2001) Radiosurgical management of benign cavernous sinus tumors: dose profiles and acute complications. Neurosurgery 48:1022–1030; discussion 1030–1032PubMedCrossRef
45.
Loeffler JS, Niemierko A, Chapman PH (2003) Second tumors after radiosurgery: tip of the iceberg or a bump in the road? Neurosurgery 52:1436–1440; discussion 1440–1442PubMedCrossRef
46.
Flickinger JC, Lunsford LD, Kondziolka D (1991) Dose-volume considerations in radiosurgery. Stereotact Funct Neurosurg 57:99–105PubMedCrossRef
47.
Marks LB, Spencer DP (1991) The influence of volume on the tolerance of the brain to radiosurgery. J Neurosurg 75:177–180PubMed
48.
Stafford SL, Pollock BE, Leavitt JA et al (2003) A study on the radiation tolerance of the optic nerves and chiasm after stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 55:1177–1181PubMedCrossRef
49.
Debus J, Hug EB, Liebsch NJ et al (1997) Brainstem tolerance to conformal radiotherapy of skull base tumors. Int J Radiat Oncol Biol Phys 39:967–975PubMedCrossRef
50.
Debus J, Hug EB, Liebsch NJ et al (1999) Dose-volume tolerance of the brainstem after high-dose radiotherapy. Front Radiat Ther Oncol 33:305–314PubMed
51.
Emami B, Lyman J, Brown A et al (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21:109–122PubMed
52.
Alheit H, Saran FH, Warrington AP et al (1999) Stereotactically guided conformal radiotherapy for meningiomas. Radiother Oncol 50:145–150PubMedCrossRef
53.
Brell M, Villa S, Teixidor P et al (2006) Fractionated stereotactic radiotherapy in the treatment of exclusive cavernous sinus meningioma: functional outcome, local control, and tolerance. Surg Neurol 65:28–33; discussion 33–34PubMedCrossRef
54.
Debus J, Wuendrich M, Pirzkall A et al (2001) High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. J Clin Oncol 19:3547–3553PubMed
55.
Milker-Zabel S, Zabel-du Bois A, Huber P et al (2006) Fractionated stereotactic radiation therapy in the management of benign cavernous sinus meningiomas: long-term experience and review of the literature. Strahlenther Onkol 182:635–640PubMedCrossRef
56.
Steinvorth S, Welzel G, Fuss M et al (2003) Neuropsychological outcome after fractionated stereotactic radiotherapy (FSRT) for base of skull meningiomas: a prospective 1-year follow-up. Radiother Oncol 69:177–182PubMedCrossRef
57.
Baumert BG, Norton IA, Davis JB (2003) Intensity-modulated stereotactic radiotherapy vs. stereotactic conformal radiotherapy for the treatment of meningioma located predominantly in the skull base. Int J Radiat Oncol Biol Phys 57:580–592PubMedCrossRef
58.
Pirzkall A, Carol M, Lohr F et al (2000) Comparison of intensity-modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors. Int J Radiat Oncol Biol Phys 48:1371–1380PubMedCrossRef
59.
Pirzkall A, Debus J, Haering P et al (2003) Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience. Int J Radiat Oncol Biol Phys 55:362–372PubMedCrossRef
60.
Milker-Zabel S, Zabel-du Bois A, Huber P et al (2007) Intensity-Modulated Radiotherapy for Complex-Shaped Meningioma of the Skull Base: Long-term Experience of a Single Institution. Int J Radiat Oncol Biol Phys 68:858–863PubMed
61.
Nakamura JL, Pirzkall A, Carol MP et al (2003) Comparison of intensity-modulated radiosurgery with gamma knife radiosurgery for challenging skull base lesions. Int J Radiat Oncol Biol Phys 55:99–109PubMedCrossRef
62.
Gudjonsson O, Blomquist E, Nyberg G et al (1999) Stereotactic irradiation of skull base meningiomas with high energy protons. Acta Neurochir (Wien) 141:933–940CrossRef
63.
Vernimmen FJ, Harris JK, Wilson JA et al (2001) Stereotactic proton beam therapy of skull base meningiomas. Int J Radiat Oncol Biol Phys 49:99–105PubMedCrossRef
64.
Weber DC, Lomax AJ, Rutz HP et al (2004) Spot-scanning proton radiation therapy for recurrent, residual or untreated intracranial meningiomas. Radiother Oncol 71:251–258PubMedCrossRef
65.
Noel G, Bollet MA, Calugaru V et al (2005) Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons. Int J Radiat Oncol Biol Phys 62:1412–1422PubMedCrossRef
66.
Baumert BG, Norton IA, Lomax AJ et al (2004) Dose conformation of intensity-modulated stereotactic photon beams, proton beams, and intensity-modulated proton beams for intracranial lesions. Int J Radiat Oncol Biol Phys 60:1314–1324PubMedCrossRef
67.
Korhonen K, Salminen T, Raitanen J et al (2006) Female predominance in meningiomas can not be explained by differences in progesterone, estrogen or androgen receptor expression. J Neurooncol 80:1–7PubMedCrossRef
68.
Omulecka A, Papierz W, Nawrocka-Kunecka A et al (2006) Immunohistochemical expression of progesterone and estrogen receptors in meningiomas. Folia Neuropathol 44:111–115PubMed
69.
Wolfsberger S, Doostkam S, Boecher-Schwarz HG et al (2004) Progesterone-receptor index in meningiomas: correlation with clinico-pathologial parameters and review of the literature. Neurosurg Rev 27:238–245PubMed
70.
Perry A, Cai D, Scheithauer B et al (2000) Merlin, DAL-1 and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 59:872–879PubMed
71.
Fewings P, Battersby R, Timperley W (2000) Long-term followup of progesterone receptor status in benign meningioma: a prognostic indicator of recurrence? J Neurosurg 92:401–405PubMed
72.
Pravdenkova S, Al-Mefty O, Sawyer J et al (2006) Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg 105: 163–173PubMed
73.
Maiuri F, De Caro Mdel B, Esposito F et al (2007) Recurrences of meningiomas: predictive value of pathologic features and hormonal and growth factors. J Neuroncol 82:63–68CrossRef
74.
Maiuri F, Montagnani S, Gallicchio B et al (1989) Oestrogen and progesterone sensitivity in cultured meningioma cells. Neurol Res 11:9–13PubMed
75.
Adams E, Schrell U, Fahlbusch R et al (1990) Hormonal dependency of cerebral meningiomas. Part 2: In vitro effects of steroids, bromocriptine, and epidermal growth factor receptor on growth of meningiomas. J Neurosurg 73:750–755PubMed
76.
Lamberts SW, Tanghe HL, Avezaat CJ et al (1992) Mifepristone (RU 486) treatment of meningiomas. J Neurol Neurosurg Psychiatry 55:486–490PubMed
77.
Grunberg SM, Weis MH, Spitz IM, Ahmadi J, Sudan J, Russell CA, Lucci L, Stevenson LL (1991) Treatment of unresectable meningiomas with the anti-progesterone agent mifepristone. J Neurosurg 74:861–866PubMed
78.
Grunberg SM, Weiss MH, Russell CA et al (2006) Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest 24:727–733PubMedCrossRef
79.
Ragel BT, Gillespie DL, Kushnir V et al (2006) Calcium channel antagonists augment hydroxyurea and RU486-induced inhibition of meningioma growth in vivo and in vitro. Neurosurgery 59:1109–1120PubMedCrossRef
80.
Goodwin J, Crowley J, Eyre H et al (1993) A phase II evaluation of Tamoxifen in unresectable or refrqactory meningiomas: a southweast Oncology Group study. J Neurooncol 15:75–77PubMedCrossRef
81.
Schrell UM, Rittig MG, Anders M et al (1977) Hydroxyurea for treatment of unresectable and recurrent meningiomas. II Decrease in size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86:840–844
82.
Mason WP, Gentili F, Mac Donald DR, Hariharan S, Cruz CR Abrey LE (2002) Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97:341–346PubMed
83.
Newton HB, Scott SR, Volpi C (2004) Hydroxyurea chemotherapy for meningiomas: Enlarged cohort with extended follow-up. Br J Neurosurg 18:495–499PubMedCrossRef
84.
Hahn BM, Schrell Um, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG (2005) Prolonged oral hydroxyurea and concurrent 3-d conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol 74:157–165PubMedCrossRef
85.
Loven D, Hardoff R, Sever ZB, Steunmetz AP, Gornish M, Rappaport ZH, Fenig E, Ram Z, Sulkes A (2004) Nonresectable slow growing meningiomas treated with hydroxyurea. J Neurooncol 67:221–226PubMedCrossRef
86.
Chamberlain MC, Tsao-Wei DD, Groshen S (2004) Temozolomide for treatment-resistant recurrent meningioma. Neurology 62:1210–1212PubMed
87.
Chamberlain MC, Tsao-Wei DD, Groshen S (2006) Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neuroncol 78:271–276CrossRef
88.
Kaba SE, DeMonte F, Bruner JM et al (1997) The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 40:271–275PubMedCrossRef
89.
Perry A, Gutmann DH, Reifenberger G (2004) Molecular pathogenesis of meningiomas. J Neuro-Oncol 70:183–202CrossRef
90.
Gusella JF, Ramesh V, MacCollin M et al (1999) Merlin: the neurofibromatosis 2 tumor suppressor. Biochem Biophys Acta 1423:M29–36PubMed
91.
McClatchey AI, Giovannini M (2005) Membrane organization and tumorigenesis- the NF2 tumor suppressor, Merlin. Genes Dev 19: 2265–2277PubMedCrossRef
92.
Wellenreuther R, Kraus JA, Lenartz D et al (1995) Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol 146:827–833PubMed
93.
Vogel Y, Lenartz D, Schramm J et al (1997) Quantitative analysis of neurfibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants. Lab Invest 77:601–606PubMed
94.
Rutledge MH, Sarrazin J, Rangaratnam S et al (1994) Evidence for complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 6:180–184CrossRef
95.
Lee JH, Sundaram V, Stein DJ et al (1997) Reduced expression of Schwannomin/Merlin in human sporadic meningiomas. Neurosurgery 40:578–587PubMedCrossRef
96.
Antinheimo J, Haapasalo H, Haltia M et al (1997) Proliferation potential and histological features in neurofibromatosis 2-associated and sporadic meningiomas. J Neurosurg 87:610–614PubMedCrossRef
97.
Lamszus K, Vahldeik F, Mautner VF et al (2000) Allelic losses in neurofibromatosis 2-associated meningiomas. J Neuropathol Exp Neurol 59:504–512PubMed
98.
Dumanski JP, Rouleau GA, Nordenskjold M et al (1990) Molecular genetic analysis of chromosome 22 in 81 cases of meningioma. Cancer Res 50:5863–5867PubMed
99.
Weisman AS, Raguet SS, Kelly PA (1987) Characterization of the epidermal growth factor receptor in human meningioma. Cancer Res 47:2172–2176PubMed
100.
Jones NR, Rossi ML, Gregoriou M et al (1990) Epidermal growth factor receptor expression in 72 meningiomas. Cancer 66:152–155PubMedCrossRef
101.
Johnson MD, Horiba M, Arteaga C (1994) The epidermal growth factor receptor is associated with phospholipase C γ in meningiomas. Human Pathol 25:146–153CrossRef
102.
Carroll RS, Black PM, Zhang J et al (1997) Expression and activation of epidermal growth factor receptors in meningiomas. J Neurosurg 87:315–323PubMed
103.
Wang J-L, Nister M, Hermansson M, Westermark B et al (1990) Expression of PDGF β-receptors in human meningioma cells. Int. J. Cancer 46:772–778PubMedCrossRef
104.
Maxwell M, Galanopoulos T, Hedley-Whyte ET et al (1990) Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products. Int J Cancer 46:16–21PubMedCrossRef
105.
Shamah SM, ALberta JA, Giannobile WV et al (1997) Detection of activated platlet-derived growth factor receptors in human meningioma. Cancer Res 57:4141–4147PubMed
106.
Lingood RM, Hsu DW, Efird JT et al (1995) TGF-alpha expression in meningioma-tumor progression and therapeutic response. J Neuro-Oncol 26:45–51CrossRef
107.
Hsu QW, Efird JT, Hedley-Whyte ET (1998) MIB-1(Ki-67) index and transforming growth factor alpha (TGF-alpha) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurobiol 24:441–452PubMedCrossRef
108.
Van Setten GB, Edstrom L, Stibler H et al (1999) Levels of transforming growth factor alpha (TGF-α) in human cerebrospinal fluid. Int J Dev Neurosci 17:131–134PubMedCrossRef
109.
Adams EF, Schrell UMH, Thieruf P et al (1991) Autocrine control of human meningioma proliferation: secretion of platelet-derived growth factor-like molecules. Int J Cancer 49:398–402PubMedCrossRef
110.
Todo T, Adams EF, Fahlbusch R et al (1996) Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurgery 84:852–859
111.
Nister M, Enbland P, Backstrom G et al (1994) Platelet-derived growth factor (PDGF) in neoplastic and non-neoplastic cystic lesions of the central nervous system and in the cerebrospinal fluid. Br J Cancer 69:952–956PubMed
112.
Pronk GL, Bos JL (1994) The role of p21 ras in receptor tyrosine kinase signaling. Biochim Biophys Acta 1198:131–147PubMed
113.
114.
Shu J, Lee JH, Harwalkar JA et al (1999) Adenovirus-mediated gene transfer of dominant negative H-ras inhibits proliferation of primary meningioma cells. Neurosurgery 44:579–587PubMedCrossRef
115.
Lewis TS, Shapiro PS, Ahn NG (1998) Signal transduction through MAP Kinase cascades. Adv Cancer Res 74:49–139PubMed
116.
Marshall MS (1995) Ras target proteins in eukaryotic cells. FASEB J 9:1311–1318PubMed
117.
Kock W (2000) Meaningful relationships: the regulation of the Ras/Raf/Mek/ERK pathway by protein interactions. Biochem J 351:289–305CrossRef
118.
Sivaraman VS, Wang H, Nuvovo GJ et al (1997) Hyperexpression of mitogen-activated kinase in human breast carcinoma. J Clin Invst 7:1478–1483CrossRef
119.
Mandell JW, Hussaini IM, Zecevic M et al (1998) In situ visualization of intratumor growth factor signaling. Am J Pathol 153:1411–1423PubMed
120.
Johnson MD, Woodard A, Kim P et al (2001) Evidence for mitogen associated protein kinase activation and transduction of mitogenic signals from platelet derived growth factor in human meningioma cells. J Neurosurg 94:303–310
121.
Mawrin C, Sasse T, Kirches E et al (2005) Different activation of mitogen activated protein kinase and Akt signalling is associated with aggressive phenotype of human meningiomas. Clin Cancer Res 11:4074–4082PubMedCrossRef
122.
Nicholson KM, Anderson NG (2002) The Akt/PKB signaling pathway in human malignancy. Cell Signal 14:381–395PubMedCrossRef
123.
Walker TR, Moore SM, Lawson MF et al (1998) Platelet-derived growth factor-BB and thrombin activate phophoinositide 3-kinase and protein kinase B: Role in mediating airway smooth muscle proliferation. Mol Pharmacol 54:1007–1015PubMed
124.
Roche S, Koegl M, Courtneidge SA (1994) The phosphatidylinositol 3-kinase A is required for DNA synthesis by some but not all growth factors. PNAS 91:9185–9189PubMedCrossRef
125.
Shayesteh L, Lu Y, Kuo W-L et al (1999) PI3KCA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99–102PubMedCrossRef
126.
Sun M, Wang G, Paciga JE et al (2001) AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH33T3 cells. Am J Pathol 159:431–437PubMed
127.
Johnson MD, Okediji E, Woodard A el al (2002) Evidence for Phosphatidylinositol 3-Kinase Akt-p70S6K Pathway Activation and Transduction of Mitogenic Signals by Platelet Derived Growth Factor in Human Meningioma Cells J Neurosurg 97:668–675PubMed
128.
Conway A-M, Rakhit S, Pyne S et al (1999) Platelet-derived-growth-factor stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: role pertussis-toxin-sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase. Biochem J 337:171–177PubMedCrossRef
129.
Yart A, Laffargue M, Mayeux P et al (2001) A critical role for phosphoinositide 3-kinase upstream of Gab 1 and SHP2 in the activation of Ras and mitogen-activated protein kinase by epidermal growth factor. J Biol Chem 276:8856–8864PubMedCrossRef
130.
Song G, Ouyang G, Bao S (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9:59–71PubMedCrossRef
131.
Lin L-L, Wartmann M, Lin AY et al (1993) cPLA2 is phosphorylated and activated by MAP kinase. Cell 27:269–278CrossRef
132.
Castelli MG, Chiabrando C, Fanelli R et al (1989) Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 15:1505–1508
133.
Gaetani P, Butti G, Chiabrando C et al (1991) A study of the biological behavior of human brain tumors. Part I. Arachidonic acid metabolism and DNA content. J Neuro-Oncol 10:233–240
134.
Wang D, Buchanan FG, Wang H et al (2005) Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 65:1822–1829PubMedCrossRef
135.
Dannenberg AJ, Subbaramaiah K (2003) Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell 4:431–436PubMedCrossRef
136.
Pai R, Soreghan B, Szabo Il et al (2002) Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting cancer growth and gastrointestinal hypertrophy. Nat Med 8:289–293PubMedCrossRef
137.
Wang Z, Gluck S, Zhang L et al (1998) Requirement for phospholipase C-1 enzymatic activity in growth factor-induced mitogenesis. Mol Cell Biol 18:590–597PubMed
138.
Wahl MI, Olashaw NE, Nishibe S et al (1989) Platelet-derived growth factor induces rapid and sustained tyrosine phosphorylation of phospholipase C-γ in quiescent BALB/c 3T3 cells. Mol Cell Biol 9:2934–2943PubMed
139.
Buckley CT, Sekiya F, Kim YJ et al (2004) Identificationof phospholipase C-1 as a mitogen-activated protein kinase substrate. J Biol Chem 40:41807–41814CrossRef
140.
Harari PM (2004) Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11:689–708PubMedCrossRef
141.
Singer CF, Hudelist G, Lamm W et al (2004) Expression of tyrosine kinases in human malignancies as potential targets for kinase specific inhibitors. Endocrine-related Cancer 11:861–869PubMedCrossRef
142.
Huang S, Armstrong EA, Benavente S et al (2004) Dual-agent targeting of the epidermal growth factor (EGFR): combining anti-EGFR antibody and tyrosine kinase inhibitor. Cancer Res 64:5355–5362PubMedCrossRef
143.
Rich Jn, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:132–142
144.
Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M et al (2006) Phase I study of erlotinib HCL alone and combined with temozolamide in patients with stable or recurrent malignant glioma. Neuro Oncology 8:67–78PubMedCrossRef
145.
Vogelbaum MA, Peereboom D, Stevens G, Barnett G, Brewer C (2004) Phase II rial of EGFR tyrosien kines inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results. Proc Am Soc Oncol 22:1558a
146.
Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan Zhu S Dia EQ et al (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2202PubMedCrossRef
147.
Lassman AB, Abrey LE, Gilbert MR (2006) Response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 354:525–526PubMedCrossRef
148.
Giaccone G, Johnson DH, Manegold C et al (2002) A phase III clinical trial of ZD1839 (“Iressa”) in combination with gemcitabine and cisplatin in chemotherapy naïve patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 13(Suppl 5):2–3
149.
Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND et al (2005) Epidermal growth factor receptor, protein kinase B/Akt and glioma response to erlotinib. J Natl Cancer Inst 97:880–887PubMedCrossRef
150.
Torrance CJ, Jackson PE, Montgomery E et al (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:1024–1028PubMedCrossRef
151.
Eller JL, Longo SL, Kyle MM, Bassano D, Hicklin D, Canute G (2005) Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 56:155–162PubMed
152.
Combs SE, Heeger S, Haselmann R, Edler L, Debus J, Schulz-Ertner D (2006). Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolamide (GERT) – phase I/II trial: study protocol. BMC Cancer 6: 133–140PubMedCrossRef
153.
Haluska P, Dy GK, Adjei AA (2002) Farnesyl transferase inhibitors as anticancer agents. European J Cancer 38:1685–1700CrossRef
154.
Appels NM, Beijnen JH, Schellens JH (2005) Development of farnesyl transferase inhibitors: a review. Oncologist 10:565–578PubMedCrossRef
155.
Johnson MD, Woodard A, Okediji EJ et al (2002) Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase. J Neuro-Oncol 56:133–142CrossRef
156.
Kohno M, Pouyssegur J (2006) Targeting the ERK signaling pathway in cancer therapy. Ann Med 38:200–211PubMedCrossRef
157.
Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS (2003) Analysis of the phosphatidylinositol 3-kinase signaling pathway in glioblastoma patients in vivo. Caner Res 63:2742–2746
158.
Nakamura JL, Karlsson A, Arvold ND, Gottschalk Ar, Pieper RO, Stokoe D, Haas-Kogan DA (2005) PKB/Akt mediates radiosensitization by signaling inhibitor LY294002 in human malignant gliomas. J Neuroncol 71:215–222CrossRef
159.
Witzig TE, Kaufmann SH (2006) Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 7:285–294PubMedCrossRef
160.
Ragel BT, Jensen RL, Gillespie DL, Prescott SM Couldwell WT (2005) Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic implications. J Neurosurg 103:508–517PubMed
161.
Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, Dubois RN (2005) Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol 23:254–266PubMedCrossRef
162.
Paek SH, Kim CY, Kim YY, Park IA, Kim MS, Kim DG, Jung HW (2002) Correlation of clinical and biological parameters with peritumoral edema in meningiomas. J Neurooncol 60:235–45PubMedCrossRef
163.
Singer CF, Hudelist G, Lamm W et al (2004) Expression of tyrosine kinases in human malignancies as potential targets for kinase specific malignancies. Cancer 11:861–869
Metadata
Title
New prospects for management and treatment of inoperable and recurrent skull base meningiomas
Authors
Mahlon D. Johnson
Burak Sade
Michael T. Milano
Joung H. Lee
Steven A. Toms
Publication date
01-01-2008
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 1/2008
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-007-9434-z

Other articles of this Issue 1/2008

Journal of Neuro-Oncology 1/2008 Go to the issue

Lab. Investigation-Human/Animal Tissue

Molecular and cellular response of the most extensively used rodent glioma models to radiation and/or cisplatin

Lab. Investigation-human/animal tissue

Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death

Lab. Investigation-Human/Animal Tissue

Construction of double suicide genes system controlled by MDR1 promoter with targeted expression in drug-resistant glioma cells

Editorial

Editors’ Message to the Readership

Clinical-Patient Studies

Outcome and tolerability of topiramate in brain tumor associated epilepsy

Clinical Study - patient studies

A case of ‘lymphomatosis cerebri’ diagnosed in an early phase and treated by whole brain radiation: case report and literature review